Lupin has offered an update on expected US Food and Drug Administration action on its proposed Spiriva (tiotropium) generic as it reported results for its financial third quarter that reflected both turnover growth and increased profitability.
The firm now expects FDA action on its tiotropium filing in either April or July, depending on whether the agency...







